Analysis reveals overall survival differences in chronic lymphocytic leukemia treatment sequences, suggesting further evaluation is needed.
Key Points
Overall survival was significantly different for some treatment sequences in CLL/SLL patients.
Chronic lymphocytic leukemia patients receiving chemoimmunotherapy after anti-CD20 monoclonal antibody had a hazard ratio of 1.95 for worse overall survival.
Observational analysis of treatment regimens used in 2354 patients from a large health record database.
The findings highlight the need for renewed assessment of treatment sequences as new therapies are introduced.